Stockreport

Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights

Biomea Fusion, Inc.  (BMEA) 
PDF Initiated two Phase II trials COVALENT-211 and COVALENT-212 (icovamenib in type 2 diabetes) with 26-week primary endpoint data anticipated in the fourth quarter of 2026C [Read more]